KAMADA LTD business relationships
Companies named in KAMADA LTD’s 20-F filed 2026-03-11, and public companies whose annual reports name KAMADA LTD. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in KAMADA LTD’s annual report 16
“are in the United States (by Takeda) and, commencing in 2024, GLASSIA is also being sold by Takeda in Canada, through our companies'” SEC filing
“largest customers, Kedrion, Takeda and Clalit Health Services accounted for 23%, 11% and 7%, respectively, of our total revenues.” SEC filing
“the end of 2023, GLASSIA was distributed by Takeda only in the United States and, commencing in 2024, also in Canada); (2) a technology” SEC filing
“Commencing 2022, the Company collected royalty payments from Takeda” SEC filing
“Pursuant to our licensing agreement with Takeda, we are entitled to a guaranteed minimum of” SEC filing
“Takeda, our strategic partner for sales of GLASSIA” SEC filing
“| our expectation to continue manufacturing HEPAGAM B, VARIZIG and WINRHO SDF at Emergent BioSolutions Inc. ("Emergent") in the foreseeable future, and our plan to transition the manufacturing of these products to our manufacturing facility in Beit Kama, Israel, which would require certain changes t...” SEC filing
“In addition, we rely on Takeda,” SEC filing
“with the partnership arrangement with Baxter (now Takeda), we signed a fraction IV paste supply agreement with Baxter (now Takeda) for” SEC filing
“with the partnership arrangement with Baxter (now Takeda), we signed a fraction IV paste supply agreement with Baxter (now Takeda) for” SEC filing
“CMV hyper-immune plasma for the manufacturing of CYTOGAM is supplied by CSL Behring Ltd. ("CSL Behring") through a dedicated” SEC filing
“Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S.p.A, Bio Products Laboratories ("BPL") Valneva SE and Mabxience, which are” SEC filing
“For the year ended December 31, 2024, sales to our three largest customers, Kedrion, Takeda and McKesson, one of the largest U.S.-based” SEC filing
“Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S.p.A, Bio Products Laboratories ("BPL") Valneva SE and Mabxience, which are” SEC filing
“| Fifth Amendment to the Supply and Distribution Agreement, by and between Kamada Ltd. and Kedrion Biopharma Inc., dated January 1, 2025. (incorporated by reference to Exhibit 4.41 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 5, 2025) |” SEC filing
“we secured supply agreements with multiple suppliers, including Kedrion, for the manufacturing of KEDRAB and KAMRAB, CSL Behring for the” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.